

EKF Diagnostics Holdings plc
("EKF" or the "Company")

PDMR/ PCA

Dealings

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed point-of-care business, announces that the Board of EKF has been informed that on Friday 1 October, 2021, certain funds connected to Christopher Mills, Non-executive Chairman, sold a total of 1,275,000 ordinary shares of 1 pence each in the Company ("Ordinary Shares") at a price of 84.0 pence per Ordinary Share.

Following this transaction, Christopher Mills' total direct and indirect interest in the Company is 130,875,000 Ordinary Shares, representing approximately 28.76% of the total voting rights over the Company's issued share capital.

The Notification of Dealing Form required in accordance with UK MAR is set out below and reflects the sale of 637,500 Ordinary Shares by each of the North Atlantic Smaller Companies Investment Trust plc ("NASCIT") and the Oryx International Growth Fund Limited ("Oryx").

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1 Details of the person discharging managerial responsibilities / person closely associated

a) Name Christopher Mills

2 Reason for the notification

- a) Position/status Christopher Mills is Non-executive Chairman of the Company.
- Mr. Mills is a partner and Chief Investment Officer of Harwood Capital LLP. Harwood Capital LLP is Investment Manager to NASCIT.
- Mr Mills is also a director of Harwood Capital Management (Gibraltar) Limited, which is Investment Manager and Investment Adviser to Oryx.
- b) Initial notification /Amendment Initial Notification

3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name EKF Diagnostics Holdings plc
- b) LEI 213800DXTF3EAUUK1AR05

4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

- a) Description of the financial instrument, type of instrument Ordinary shares of £0.01 each
- Identification code GB0031509804
- b) Nature of the transaction Sale of shares
- c) Price(s) and volume(s)
- | | Price(s) | Volume(s) |
|--|----------|-----------|
| | £0.84 | 637,500 |
| | £0.84 | 637,500 |
- d) Aggregated information
- Aggregated volume 1,275,000
 - Price £0.84
- e) Date of the transaction 1 October 2021
- f) Place of the transaction London Stock Exchange

EKF Diagnostics Holdings plc
 Christopher Mills, Non-executive Chairman
 Mike Salter, CEO
 Richard Evans, FD & COO

www.ekfdiagnostics.com
Tel: +44 (0)29 2071 0570

Singer Capital Markets (Nominated Adviser & Joint Broker) **Tel: +44 (0)20 7496 3000**

Aubrey Powell / George Tzimas / Tom Salvesen

Investec Bank plc (Joint Broker)
Gary Clarence / Daniel Adams

Tel: +44 (0)20 7597 4000

Walbrook PR Limited
Paul McManus / Lianne Cawthorne

Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com
Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHUPGCCUUPGGWA admin PDMR/ PCA Dealings 32170585 A Tue, 10/05/2021 - 15:00 LSE RNS
Directors' Dealings EKF